cytoVation

Developing next generation lytic immunotherapies for solid tumours

[cytoVation @cytoVation]

Common skin papillomas or warts are a widespread problem which can be debilitating for some https://t.co/IxUTsldTSf

[cytoVation @cytoVation]

Research has been published in @NatureNews that reinforces the mechanism of action of Cytovation’s peptides #cancer https://t.co/5mhH2WWOzF

[cytoVation @cytoVation]

Cytovation is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway. The company is currently developing CyPep-1 for the treatment of benign skin tumours including cutaneous warts https://t.co/sfYjSjwJJo

[cytoVation @cytoVation]

New research has been published in @NatureNews that reinforces the mechanism of action of Cytovation’s peptides #cancer https://t.co/jIuZW69bwo

[cytoVation @cytoVation]

New research published in @NatureNews reinforces the mechanism of action of Cytovation’s peptides #cancer https://t.co/5mhH2WWOzF

[cytoVation @cytoVation]

'NHS England publishes guidelines curbing OTC prescriptions' - via @PharmaTimes https://t.co/o35PQA6Ncx

[cytoVation @cytoVation]

'NHS crackdown on OTC prescribing' for treatments including warts https://t.co/yjdX2wT6t3

[cytoVation @cytoVation]

We featured in @PharmaScrip as an emerging company, having raised funds to support clinical studies of our potential first-in-class viralytic & oncolytic peptide CyPep:
'Cytovation identifies unique peptide for treatment of Cutaneous warts’ 🔒 https://t.co/aN7ya3soDa

[cytoVation @cytoVation]

Pleased to be featured in @PharmaScrip as an emerging company, having raised funds to support initial clinical studies of our potential first-in-class viralytic & oncolytic peptide:
'Cytovation identifies unique peptide for treatment of Cutaneous warts’ 🔒 https://t.co/aN7ya3soDa

[cytoVation @cytoVation]

@merckgroup to buy virus-based cancer drug firm Viralytics for $394 million https://t.co/sPhtuPijAZ

[cytoVation @cytoVation]

@merckgroup to buy virus-based cancer drug firm Viralytics for $394 million https://t.co/sPhtuPijAZ

[Labiotech.eu @Labiotech_eu]

Wart is that! Never mind, @cytoVation got rid of it 😎 - #HPV #biotech https://t.co/YAeXZEgqt3

[cytoVation @cytoVation]

'Cytovation completes financing round of 30 million NOK' - via @NLifeScience https://t.co/pb5ygwq9Fb

[cytoVation @cytoVation]

Cytovation has completed a NOK 30m financing round to progress CyPep-H1 through Phase I/IIa clinical study in cutaneous warts https://t.co/SYyU3yocs3

[cytoVation @cytoVation]

'Cytovation has raised over €3M to finish off pre-clinical testing of its treatment for warts, and to take it into the clinic' - via @Labiotech_eu https://t.co/l49HSCJ9pk

[cytoVation @cytoVation]

Cytovation completes NOK 30m financing round to progress CyPep-H1 through Phase I/IIa clinical study in cutaneous warts https://t.co/SYyU3yocs3

[cytoVation @cytoVation]

Cytovation's product pipeline is focused on tackling common dermatological diseases which have a debilitating impact https://t.co/oEoeBDbqfC

[cytoVation @cytoVation]

Cytovation chairman Per Eystein Lønning has published a paper in Cancer Cell https://t.co/jSybdV3Poa

[cytoVation @cytoVation]

Overview of the Human Papillomavirus (HPV) associated cancer (oncology) pipeline landscape https://t.co/7l7dCALQIa

[cytoVation @cytoVation]

'Norwegian researchers with new breast cancer breakthrough' - via VG News Norway https://t.co/14iUN1rxCG

[cytoVation @cytoVation]

Cytovation chairman Per Eystein Lønning has published a new paper in Cancer Cell https://t.co/jSybdV3Poa